ICUS Weekly News Monitor 3-22-2018


 
 
 
  1. Dove Press, Ultrasound molecular imaging of breast cancer in MCF-7 orthotopic mice using gold nanoshelled poly(lactic-co-glycolic acid) nanocapsules: a novel dual-targeted ultrasound contrast agent, March 21, 2018 Authors: Li Xu, et al
  2. Uro Today, EAU 2018: Prostate Cancer Diagnosis by Three-Dimensional Contrast-Ultrasound Dispersion Imaging, March 2018 Presented by: Massimo Mischi, MD, et al.
  3. Journal of Kidney Cancer and VHL, Contrast-Enhanced Ultrasound-Guided Radiofrequency Ablation of Renal Tumors, Feb, 2018 Authors: Dan O’Neal, et al
  4. Echo Research and Practice, Discounted open access publishing

 

Dove Press

Ultrasound molecular imaging of breast cancer in MCF-7 orthotopic mice using gold nanoshelled poly(lactic-co-glycolic acid) nanocapsules: a novel dual-targeted ultrasound contrast agent

March 21, 2018

Authors: Li Xu,1,* Jing Du,1,* Caifeng Wan,1 Yu Zhang,1 Shaowei Xie,1 Hongli Li,1 Hong Yang,2 Fenghua Li1

1Department of Ultrasound, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China; 2Department of Chemistry, College of Life and Environmental Science, Shanghai Normal University, Shanghai, China

*These authors contributed equally to this work

Published 21 March 2018 Volume 2018:13 Pages 1791—1807

  1. DOI https://doi.org/10.2147/IJN.S153993

Abstract

Background: The development of nanoscale molecularly targeted ultrasound contrast agents (UCAs) with high affinity and specificity is critical for ultrasound molecular imaging in the early detection of breast cancer.

Purpose: To prospectively evaluate ultrasound molecular imaging with dual-targeted gold nanoshelled poly(lactide-co-glycolic acid) nanocapsules carrying vascular endothelial growth factor receptor type 2 (VEGFR2) and p53 antibodies (DNCs) in MCF-7 orthotopic mice model.

Methods: DNCs were fabricated with an inner PLGA and outer gold nanoshell spherical structure. Its targeting capabilities were evaluated by confocal laser scanning microscopy (CLSM) and flow cytometry (FCM) in vitro. Contrast-enhanced ultrasound imaging (CEUS) with DNCs was evaluated qualitatively and quantitatively in vitro and in MCF-7 orthotopic mice model by two different systems. The biodistribution of NCs in mice was preliminary investigated. Differences were calculated by using analysis of variance.

Results: DNCs showed a well-defined spherical morphology with an average diameter of 276.90±110.50 nm. In vitro, DNCs exhibited high target specificities (79.01±5.63% vs. 2.11±1.07%, P<0.01; 75.54±6.58% vs. 5.21±3.12%, P<0.01) in VEGFR2- and p53-positive cells compared with control cells. In vivo, CEUS displayed a significantly higher video intensity in two systems using DNCs in comparison with non-targeted PLGA@Au NCs and single-targeted NCs. Biodistribution studies revealed that more DNCs in breast cancer tissue could be detected in mice than in other NCs (P<0.05).

Conclusion: DNCs were demonstrated to be novel dual-targeted UCAs and may have potential applications in early non-invasive visualization of breast cancer.

 
 
 
 
 
 

Uro Today

EAU 2018: Prostate Cancer Diagnosis by Three-Dimensional Contrast-Ultrasound Dispersion Imaging

March 2018

Presented by: Massimo Mischi, MD Eindhoven University of Technology, Eindhoven, The Netherlands

Co-Authors: Schalk S, Huang J, Li J, Wijkstra H, Huang P

Written by: Zachary Klaassen, MD, Urologic Oncology Fellow, University of Toronto, Princess Margaret Cancer Centre, twitter: @zklaassen_md at the 2018 European Association of Urology Meeting EAU18, 16-20 March, 2018 Copenhagen, Denmark

Dr. Mischi and colleagues presented results of their experience using 3-D contrast ultrasound dispersion imaging. Dynamic contrast-enhanced ultrasound (DCE-US) provides the opportunity to localize prostate cancer by detection of an associated angiogenic processes. As such, dedicated DCE-US methods have been proposed, however until now these methods have been validated in 2D only, requiring the injection of an ultrasound contrast agent bolus for the analysis of each imaging plane. The need for multiple injections hampers the value of these methods for routine clinical practice. A 3D approach would overcome this problem and the full prostate volume could be analyzed by injection of a single ultrasound contrast agent bolus. The objective of this study was to investigate the feasibility of 3D contrast-ultrasound dispersion imaging for prostate cancer localization.

There were 43 patients referred for 12-core systematic biopsy who underwent 3D DCE-US. For each recording, parametric maps of dispersion and standard perfusion parameters were computed.

Three dimensional contrast ultrasound dispersion imaging

Per biopsy core, the presence of malignancy and the Gleason score were reported. Each prostate was divided in 12 sections corresponding to the biopsy locations. The 90th percentile values of the parameters in each section were compared with the corresponding biopsy outcome. Sections were considered malignant when at least half of the biopsy cores were malignant; sensitivity and specificity to prostate cancer were also evaluated.

Contrast ultrasound dispersion imaging results were superior to standard perfusion parameters. Significant difference between sections corresponding to benign and malignant biopsy cores (p<0.001) was observed. The area under the receiver operating characteristic curve strongly increased for sections consisting of ≥50% malignant cores. In a left/right analysis, sensitivity and specificity were 65% and 80%; in a per-prostate analysis, they were 94% and 50%.

The authors concluded that based on this study, quantitative 3D DCE-US by dispersion imaging can detect prostate cancer. Furthermore, a 3D approach enables the investigation of the full prostate by a single contrast bolus injection, facilitating the clinical utilization of the method. However, Dr. Mischi and colleagues recommend additional, improved validation by comparison with the histopathological analysis of corresponding radical-prostatectomy specimens.

 
 
 
 
 
 

Journal of Kidney Cancer and VHL

Contrast-Enhanced Ultrasound-Guided Radiofrequency Ablation of Renal Tumors

February, 2018

Authors: Dan O’Neal1, Tal Cohen1, Cynthia Peterson2,3, Richard G. Barr1,3

1Department of Radiology, Northeastern Ohio Medical University, Rootstown, Ohio, USA; 2Kent State University, Salem, OH, USA; 3Ultrasound Training, Southwoods Imaging, Youngstown, OH, USA

Abstract

Although only limited long-term studies evaluating thermal ablation of renal masses have been performed, it appears that thermal ablation has a comparable 5-year success rate to that of partial or total nephrectomy. This technique is often used in patients who are not good candidates for partial or total nephrectomy. Contrast-enhanced ultrasound (CEUS) has been recently approved by the Food and Drug Administration for characterization of focal liver lesions in adults and pediatric patients. CEUS can be used off label for renal applications and has been used for years in Europe and Asia. It has several advantages over contrast-enhanced computed tomography for use as the technique to guide and evaluate efficacy of thermal ablation of renal masses. These include the ability to visualize small amounts of enhancement, repeat dosing to evaluate efficacy of an ablation during a procedure, thin slice thickness, and real-time visualization. Ultrasound contrast is also non-nephrotoxic and non-hepatotoxic, allowing evaluation of patients with renal insufficiency. This article reviews the use of CEUS for the guidance and follow-up of thermal ablative procedures of renal masses.

Author for correspondence: Richard G. Barr, Northeastern Ohio Medical University, Southwoods Imaging, 7623 Market Street, Youngstown, OH 44512, USA. Email: This email address is being protected from spambots. You need JavaScript enabled to view it. This email address is being protected from spambots. You need JavaScript enabled to view it.

How to cite: O’Neal D et al. Contrast-enhanced ultrasound-guided radiofrequency ablation of renal tumors. J Kidney Cancer VHL 2018; 5(1):7–14. DOI: http://dx.doi.org/10.15586/jkcvhl.2018.100

Copyright: O’Neal D et al.

 
 
 
 
 

Echo Research and Practice

Discounted open access publishing

Echo Research and Practiceis an open-access journal dedicated to publishing the latest research on echocardiography and its associated imaging modalities.  ICUS members are entitled to a 25% discount on the open-access publishing charge. The journal is indexed in Scopus, PubMed and the Web of Science’s Emerging Sources Citation Index.

Find out more at: www.echorespract.com  

ICUS Sponsors

ICUS gratefully acknowledges its 2017 sponsors:

dentons-logo2

silver-level

samsung-logo

siemens-new-original

philips-icus-logo

Contact ICUS

  • Address: 1900 K Street, N.W.
    Washington, DC 20006-1102, USA
  • Telephone: 202-408-6199

About ICUS

ICUS is the world’s only professional society exclusively devoted to contrast-enhanced ultrasound (CEUS) medical imaging technology.

Learn more...

You are here: Home ICUS Weekly News Monitors ICUS Weekly News Monitor 3-22-2018